Antihypoxic formulation

Details Antihypoxic formulation Antihypoxic formulation

1994-04-18

1995-08-08

Rose, Shep K.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 45, A61K 31455, A61K 3152, A61K 3842, A61K 3170

Patent

active

054398835

ABSTRACT:
The invention relates to cardiology, and provides an antihypoxic formulation, Energostim, including cytochrome C, nicotinamide adenine dinucleotide and inosine.
Energostim provides a complete normalization of energy metabolism and the recovery of oxygene deficiency in heart, brain, liver and other internals.

REFERENCES:
Karsanov et al VOPR. Med Khim 39/4:50-55 1993 B.A. 96:133243.
Karsanov et al 12V. Akad. Navk. Gvr2 SSR Ser Biol 9(5):230-241 BA 78.177882 (1990).
Irgashev et al Farmakol Tuksikol 51(5):41-44 Lgt Oct. 1988 Medline 89091415.
Zalewski et al Am. Heart J. 113(1):124-9 Jan 1987 Medline 87096959.
Snider et al Int. J. Sport. Nutr. 2(3):272-286 Sep. 1992 Medline 93230289.
Kostin et al Farmacol Toksikol 52(6):49-52 Nov. Dec. 1989 Medline 90/69029.

Affiliated with

Also associated with

Rating

Antihypoxic formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antihypoxic formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antihypoxic formulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-971152